XenoPort appoints Dr David Stamler chief medical officer
This article was originally published in Scrip
Executive Summary
XenoPort (US) has named Dr David Stamler senior vice-president and chief medical officer. He has more than 15 years' clinical development experience, most recently as the chief scientific officer and head of drug development for Prestwick Pharmaceuticals.